RESPONSE BY STAGE IN CD30‐POSITIVE (CD30+) CUTANEOUS T CELL LYMPHOMA (CTCL) PATIENTS RECEIVING BRENTUXIMAB VEDOTIN (BV) VS PHYSICIAN'S CHOICE (PC) IN THE PHASE 3 ALCANZA STUDY. (June 2017) - Horwitz, S.; Whittaker, S.; Duvic, M.; Dummer, R.; Kim, Y.H.; Scarisbrick, J.; Quaglino, P.; Zinzani, P.; Wolter, P.; Eradat, H.; Sanches, J.; Ortiz‐Romero, P.; et al.